Early COVID‐19 Vaccine Initiation and Completion Among Cancer Survivors and Barriers to Vaccine Completion: Implications for Future COVID‐19 Vaccination Uptake Rates

Cancer Medicine, Journal Year: 2024, Volume and Issue: 13(22)

Published: Nov. 1, 2024

ABSTRACT Purpose Cancer survivors are considered by public health officials as a high‐risk group in the United States for severe complications from COVID‐19. We aimed to characterize patterns of early uptake COVID‐19 vaccine among cancer and determine modifiable barriers completion that can be addressed ensure future booster adherence. Methods Cross‐sectional data summer 2021 was extracted adult enrolled “All Us” research program. Vaccine determined based on receiving at least two doses. assessed sociodemographic factors, socioeconomic (education, income, insurance status, housing, employment status), Summer 2021, employing multivariable ordinal logistic regression those who were unvaccinated, had initiated uptake, completed vaccination. Results Of 514 sample, 73.7% fully vaccinated 2021. Those received no doses showed higher proportions SES barriers, medical distrust, perceived lack need barriers. Race (non‐Hispanic White vs. other) not statistically significantly associated with (OR (95% CI) = 0.94 (0.51, 1.70)), while every additional barrier, there 40% decrease 0.60 (0.48, 0.75)) odds more Higher distrust 56% 0.44, 95% CI: 0.32–0.59) 39% 0.61, 0.43–0.87) lower odds, respectively. Conclusion Racial/ethnic disparities may explained Addressing fostering trust enhance vaccination rates this group.

Language: Английский

Assessment of adherence to routine vaccination schedules in oncology patients

Journal of Oncology Pharmacy Practice, Journal Year: 2023, Volume and Issue: 30(8), P. 1302 - 1306

Published: Oct. 17, 2023

Introduction Patients diagnosed with cancer are at an increased risk of infection. Vaccines remain one the most critical public health strategies in limiting infectious diseases, a heightened importance patients. Data across general US population indicates that vaccine adherence rates suboptimal all adult schedules. This study aims to define within oncology population. Methods retrospective cohort includes patients new diagnosis. Vaccine administrations for COVID-19 (SARS-CoV-2), influenza, pneumococcal, tetanus/diphtheria/pertussis (TDaP), herpes zoster (RZV), human papillomavirus (HPV), and hepatitis B (hepB) were assessed. The primary outcome was complete adherence. Results Two hundred eighty-three included. median age diagnosis 63 years old, subjects females (60%). two common malignancies gastrointestinal breast 26.5% 15.2%, respectively. Suboptimal observed entire Complete only 1.4% specific as follows, SARS-CoV-2: 38.9%; influenza: 11.4%; pneumococcal: 12.7%; TDaP: 13.1%; RZV: 3.5%; HPV: 0%; hepB: 34%. Among schedules assessed, SARS-CoV-2 vaccination highest 38.9% being fully adherent 73% receiving least dose. Conclusion Lower compared currently published rates. Providers pharmacists can play role assessing counseling on before chemotherapy is initiated after remission obtained.

Language: Английский